Double bottom in GILDWonderful double bottom pattern spotted in GILD. It hasn't broken out yet. This chart is for educational purposes only. Please consult your financial advisor before making any buy or sell decision.
Next report date
Report period
Q1 2024
EPS estimate
−1.47 KCLP
Revenue estimate
6.25 TCLP
4001.587CLP
4.99 TCLP
23.86 TCLP
1.25 B
About Gilead Sciences, Inc.
Sector
Industry
CEO
Daniel P. O'Day
Website
Headquarters
Foster City
Employees (FY)
18 K
Founded
1987
FIGI
BBG00YFSDB53
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Gildgilead science is in parallel channel since last 6 years and forming bearish downward pattern.
This is not good as follow through for the long pole is missing.
Manage risks and Own profitsHere's a rotated Trade Box For GLD
PLease refere to old trade boxes to get a keymap or feel free to PM!
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where GILDCL is featured.
Frequently Asked Questions
The current price of GILDCL is 66554.000 CLP — it has decreased by 2.78% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BCS exchange GILEAD SCIENCES INC stocks are traded under the ticker GILDCL.
GILEAD SCIENCES INC is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
GILDCL stock is 2.85% volatile and has beta coefficient of 0.49. Check out the list of the most volatile stocks — is GILEAD SCIENCES INC there?
GILDCL earnings for the last quarter are 1.52 K CLP per share, whereas the estimation was 1.55 K CLP resulting in a −2.19% surprise. The estimated earnings for the next quarter are −1.47 K CLP per share. See more details about GILEAD SCIENCES INC earnings.
GILEAD SCIENCES INC revenue for the last quarter amounts to 6.27 T CLP despite the estimated figure of 6.26 T CLP. In the next quarter revenue is expected to reach 6.25 T CLP.
Yes, you can track GILEAD SCIENCES INC financials in yearly and quarterly reports right on TradingView.
GILDCL net income for the last quarter is 1.26 T CLP, while the quarter before that showed 1.95 T CLP of net income which accounts for −35.37% change. Track more GILEAD SCIENCES INC financial stats to get the full picture.
Today GILEAD SCIENCES INC has the market capitalization of 77.51 T, it has decreased by 8.63% over the last week.
Yes, GILDCL dividends are paid quarterly. The last dividend per share was 727.10 CLP. As of today, Dividend Yield (TTM)% is 4.63%. Tracking GILEAD SCIENCES INC dividends might help you take more informed decisions.
GILEAD SCIENCES INC dividend yield was 3.70% in 2023, and payout ratio reached 66.62%. The year before the numbers were 3.40% and 80.25% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, GILDCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GILEAD SCIENCES INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 18.00 K employees. See our rating of the largest employees — is GILEAD SCIENCES INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GILEAD SCIENCES INC technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GILEAD SCIENCES INC stock shows the sell signal. See more of GILEAD SCIENCES INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on GILEAD SCIENCES INC future price: according to them, GILDCL price has a max estimate of 114285.71 CLP and a min estimate of 65714.29 CLP. Read a more detailed GILEAD SCIENCES INC forecast: see what analysts think of GILEAD SCIENCES INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GILEAD SCIENCES INC EBITDA is 10.48 T CLP, and current EBITDA margin is 45.96%. See more stats in GILEAD SCIENCES INC financial statements.